NCT07417397 2026-02-18
Adjuvant TACE in HCC With High-risk Recurrence Factors
Guangxi Medical University
Phase 3 Recruiting
Clinical Trials
24 trialsNCT06921785 2026-01-09
ARTEMIDE-HCC01
AstraZeneca
Phase 3 Recruiting
NCT07322848 2026-01-07
UPGRADE
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Recruiting
NCT05317819 2025-12-18
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Polaris Group
Phase 3 Recruiting
NCT06841172 2025-08-01
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
Shandong Cancer Hospital and Institute
Phase 3 Recruiting
NCT05078047 2025-06-05
MOIO
UNICANCER
Phase 3 Recruiting
NCT05482516 2025-05-22
MRD-GI
Georgetown University
Phase 3 Recruiting
NCT05201404 2025-04-29
LIVERATION
Can-Fite BioPharma
Phase 3 Recruiting
NCT05489289 2025-03-12
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Akeso
Phase 3 Recruiting
NCT06371157 2025-03-12
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
Akeso
Phase 3 Recruiting
NCT03895359 2025-03-11
TACE
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3 Recruiting
NCT05557838 2025-02-07
TREMENDOUS
AstraZeneca
Phase 3 Recruiting
NCT06492395 2025-01-29
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
Second Affiliated Hospital of Guangzhou Medical University
Phase 3 Recruiting
NCT04803994 2025-01-07
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3 Recruiting
NCT05613478 2024-12-31
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Recruiting
NCT04868149 2024-08-15
Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS
The University of Hong Kong
Phase 3 Recruiting
NCT05594927 2024-08-07
BESTPOP
Beijing Shenogen Biomedical Co., Ltd
Phase 3 Recruiting
NCT06434753 2024-06-04
Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.
Hospital Universitari Vall d'Hebron Research Institute
Phase 3 Recruiting
NCT06201065 2024-01-11
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
Sun Yat-sen University
Phase 3 Recruiting
NCT05608200 2023-05-31
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 3 Recruiting
NCT05862337 2023-05-17
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT05476432 2022-12-09
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
Sun Yat-sen University
Phase 3 Recruiting
NCT05608213 2022-11-08
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 3 Recruiting
NCT04595864 2021-11-05
Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3 Recruiting